Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;21(3):310-319.
doi: 10.2174/0115672026332171240624100802.

Effects of PCSK9 Inhibitors on Early Neurologic Deterioration in Patients with Acute Non-Cardioembolism without Hemorrhagic Transformation After Intravenous Thrombolysis

Junjie Lei  1 , Qian Fan  1 , Xiaofeng Chen  1 , Wenbin Li  1 , Yanfang Peng  1 , Yiming Cai  1 , Xudong Liu  1 , Chenhao Liu  1 , Lei Zhang  1
Affiliations

Effects of PCSK9 Inhibitors on Early Neurologic Deterioration in Patients with Acute Non-Cardioembolism without Hemorrhagic Transformation After Intravenous Thrombolysis

Junjie Lei et al. Curr Neurovasc Res. 2024.

Abstract

Background: END (Early Neurologic Deterioration) significantly elevates the risk of morbidity and mortality. While numerous studies have investigated END following hemorrhagic transformation post-thrombolysis in acute cerebral infarction research on END without hemorrhagic transformations in patients with acute cerebral infarction due to non-cardiogenic embolism remains scarce.

Aim: This study aimed to elucidate the impact of PCSK9 inhibitors on early neurological deterioration (END) in patients with acute non-cardioembolism cerebral infarction without hemorrhagic transformation post-intravenous thrombolysis. Additionally it aimed to identify risk factors associated with END in patients suffering from this type of stroke.

Objective: The objective of this study is to investigate the effect of PCSK9 inhibitors on early neurologic deterioration (END) in patients with acute non-cardiogenic cerebral infarction without hemorrhagic transformation after intravenous thrombolysis and identify associated risk factors for END in this patient population.

Methods: In this retrospective case-control study the data of consecutive patients who underwent intravenous thrombolysis after AIS (acute ischemic stroke) without hemorrhagic transformation during hospitalization at the Stroke Center of The Fifth Affiliated Hospital of Sun Yat-sen University between January 2018 to February 2023 were retrieved and assessed. An increase of >2 in the National Institutes of Health Stroke Scale (NIHSS) within 7 days after admission was defined as END.

Results: This study included 250 patients (56 males 22.4%) they were 63.344±12.901 years old. There were 41 patients in the END group and 209 in the non-END group. The usage rate of PCSK9 inhibitors was significantly different between the END group and non-END group (29.268% vs 58.852% P<0.001). The White blood cell count (WBC) and homocysteine levels showed a significant difference between the two groups (all P<0.05). Patients not using PCSK9 inhibitors (OR=0.282 95%CI: 0.127-0.593) and white blood cell count (OR=1.197, 95%CI: 1.085-1.325) were independently associated with END. Receiver-operating characteristic curve analysis suggested that the sensitivity specificity and area under the curve for PCSK9 inhibitors used for END were 88.9%, 80.7% and 0.648 respectively.

Conclusion: The use of PCSK9 inhibitors can reduce the incidence of early neurological deterioration in patients with acute non-cardioembolism and non-hemorrhagic transformation after intravenous thrombolysis.

Keywords: PCSK9 inhibitor; acute ischemic stroke; cardioembolism; early neurologic deterioration; hemorrhagic transformation; thrombolysis..

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Feigin V.L.; Stark B.A.; Johnson C.O.; Roth G.A.; Bisignano C.; Abady G.G.; Abbasifard M.; Abbasi-Kangevari M.; Abd-Allah F.; Abedi V.; Abualhasan A.; Abu-Rmeileh N.M.E.; Abushouk A.I.; Adebayo O.M.; Agarwal G.; Agasthi P.; Ahinkorah B.O.; Ahmad S.; Ahmadi S.; Ahmed Salih Y.; Aji B.; Akbarpour S.; Akinyemi R.O.; Al Hamad H.; Alahdab F.; Alif S.M.; Alipour V.; Aljunid S.M.; Almustanyir S.; Al-Raddadi R.M.; Al-Shahi Salman R.; Alvis-Guzman N.; Ancuceanu R.; Anderlini D.; Anderson J.A.; Ansar A.; Antonazzo I.C.; Arabloo J.; Ärnlöv J.; Artanti K.D.; Aryan Z.; Asgari S.; Ashraf T.; Athar M.; Atreya A.; Ausloos M.; Baig A.A.; Baltatu O.C.; Banach M.; Barboza M.A.; Barker-Collo S.L.; Bärnighausen T.W.; Barone M.T.U.; Basu S.; Bazmandegan G.; Beghi E.; Beheshti M.; Béjot Y.; Bell A.W.; Bennett D.A.; Bensenor I.M.; Bezabhe W.M.; Bezabih Y.M.; Bhagavathula A.S.; Bhardwaj P.; Bhattacharyya K.; Bijani A.; Bikbov B.; Birhanu M.M.; Boloor A.; Bonny A.; Brauer M.; Brenner H.; Bryazka D.; Butt Z.A.; Caetano dos Santos F.L.; Campos-Nonato I.R.; Cantu-Brito C.; Carrero J.J.; Castañeda-Orjuela C.A.; Catapano A.L.; Chakraborty P.A.; Charan J.; Choudhari S.G.; Chowdhury E.K.; Chu D-T.; Chung S-C.; Colozza D.; Costa V.M.; Costanzo S.; Criqui M.H.; Dadras O.; Dagnew B.; Dai X.; Dalal K.; Damasceno A.A.M.; D’Amico E.; Dandona L.; Dandona R.; Darega Gela J.; Davletov K.; De la Cruz-Góngora V.; Desai R.; Dhamnetiya D.; Dharmaratne S.D.; Dhimal M.L.; Dhimal M.; Diaz D.; Dichgans M.; Dokova K.; Doshi R.; Douiri A.; Duncan B.B.; Eftekharzadeh S.; Ekholuenetale M.; El Nahas N.; Elgendy I.Y.; Elhadi M.; El-Jaafary S.I.; Endres M.; Endries A.Y.; Erku D.A.; Faraon E.J.A.; Farooque U.; Farzadfar F.; Feroze A.H.; Filip I.; Fischer F.; Flood D.; Gad M.M.; Gaidhane S.; Ghanei Gheshlagh R.; Ghashghaee A.; Ghith N.; Ghozali G.; Ghozy S.; Gialluisi A.; Giampaoli S.; Gilani S.A.; Gill P.S.; Gnedovskaya E.V.; Golechha M.; Goulart A.C.; Guo Y.; Gupta R.; Gupta V.B.; Gupta V.K.; Gyanwali P.; Hafezi-Nejad N.; Hamidi S.; Hanif A.; Hankey G.J.; Hargono A.; Hashi A.; Hassan T.S.; Hassen H.Y.; Havmoeller R.J.; Hay S.I.; Hayat K.; Hegazy M.I.; Herteliu C.; Holla R.; Hostiuc S.; Househ M.; Huang J.; Humayun A.; Hwang B-F.; Iacoviello L.; Iavicoli I.; Ibitoye S.E.; Ilesanmi O.S.; Ilic I.M.; Ilic M.D.; Iqbal U.; Irvani S.S.N.; Islam S.M.S.; Ismail N.E.; Iso H.; Isola G.; Iwagami M.; Jacob L.; Jain V.; Jang S-I.; Jayapal S.K.; Jayaram S.; Jayawardena R.; Jeemon P.; Jha R.P.; Johnson W.D.; Jonas J.B.; Joseph N.; Jozwiak J.J.; Jürisson M.; Kalani R.; Kalhor R.; Kalkonde Y.; Kamath A.; Kamiab Z.; Kanchan T.; Kandel H.; Karch A.; Katoto P.D.M.C.; Kayode G.A.; Keshavarz P.; Khader Y.S.; Khan E.A.; Khan I.A.; Khan M.; Khan M.A.B.; Khatib M.N.; Khubchandani J.; Kim G.R.; Kim M.S.; Kim Y.J.; Kisa A.; Kisa S.; Kivimäki M.; Kolte D.; Koolivand A.; Koulmane Laxminarayana S.L.; Koyanagi A.; Krishan K.; Krishnamoorthy V.; Krishnamurthi R.V.; Kumar G.A.; Kusuma D.; La Vecchia C.; Lacey B.; Lak H.M.; Lallukka T.; Lasrado S.; Lavados P.M.; Leonardi M.; Li B.; Li S.; Lin H.; Lin R-T.; Liu X.; Lo W.D.; Lorkowski S.; Lucchetti G.; Lutzky Saute R.; Magdy Abd El Razek H.; Magnani F.G.; Mahajan P.B.; Majeed A.; Makki A.; Malekzadeh R.; Malik A.A.; Manafi N.; Mansournia M.A.; Mantovani L.G.; Martini S.; Mazzaglia G.; Mehndiratta M.M.; Menezes R.G.; Meretoja A.; Mersha A.G.; Miao Jonasson J.; Miazgowski B.; Miazgowski T.; Michalek I.M.; Mirrakhimov E.M.; Mohammad Y.; Mohammadian-Hafshejani A.; Mohammed S.; Mokdad A.H.; Mokhayeri Y.; Molokhia M.; Moni M.A.; Montasir A.A.; Moradzadeh R.; Morawska L.; Morze J.; Muruet W.; Musa K.I.; Nagarajan A.J.; Naghavi M.; Narasimha Swamy S.; Nascimento B.R.; Negoi R.I.; Neupane Kandel S.; Nguyen T.H.; Norrving B.; Noubiap J.J.; Nwatah V.E.; Oancea B.; Odukoya O.O.; Olagunju A.T.; Orru H.; Owolabi M.O.; Padubidri J.R.; Pana A.; Parekh T.; Park E-C.; Pashazadeh Kan F.; Pathak M.; Peres M.F.P.; Perianayagam A.; Pham T-M.; Piradov M.A.; Podder V.; Polinder S.; Postma M.J.; Pourshams A.; Radfar A.; Rafiei A.; Raggi A.; Rahim F.; Rahimi-Movaghar V.; Rahman M.; Rahman M.A.; Rahmani A.M.; Rajai N.; Ranasinghe P.; Rao C.R.; Rao S.J.; Rathi P.; Rawaf D.L.; Rawaf S.; Reitsma M.B.; Renjith V.; Renzaho A.M.N.; Rezapour A.; Rodriguez J.A.B.; Roever L.; Romoli M.; Rynkiewicz A.; Sacco S.; Sadeghi M.; Saeedi Moghaddam S.; Sahebkar A.; Saif-Ur-Rahman K.M.; Salah R.; Samaei M.; Samy A.M.; Santos I.S.; Santric-Milicevic M.M.; Sarrafzadegan N.; Sathian B.; Sattin D.; Schiavolin S.; Schlaich M.P.; Schmidt M.I.; Schutte A.E.; Sepanlou S.G.; Seylani A.; Sha F.; Shahabi S.; Shaikh M.A.; Shannawaz M.; Shawon M.S.R.; Sheikh A.; Sheikhbahaei S.; Shibuya K.; Siabani S.; Silva D.A.S.; Singh J.A.; Singh J.K.; Skryabin V.Y.; Skryabina A.A.; Sobaih B.H.; Stortecky S.; Stranges S.; Tadesse E.G.; Tarigan I.U.; Temsah M-H.; Teuschl Y.; Thrift A.G.; Tonelli M.; Tovani-Palone M.R.; Tran B.X.; Tripathi M.; Tsegaye G.W.; Ullah A.; Unim B.; Unnikrishnan B.; Vakilian A.; Valadan Tahbaz S.; Vasankari T.J.; Venketasubramanian N.; Vervoort D.; Vo B.; Volovici V.; Vosoughi K.; Vu G.T.; Vu L.G.; Wafa H.A.; Waheed Y.; Wang Y.; Wijeratne T.; Winkler A.S.; Wolfe C.D.A.; Woodward M.; Wu J.H.; Wulf Hanson S.; Xu X.; Yadav L.; Yadollahpour A.; Yahyazadeh Jabbari S.H.; Yamagishi K.; Yatsuya H.; Yonemoto N.; Yu C.; Yunusa I.; Zaman M.S.; Zaman S.B.; Zamanian M.; Zand R.; Zandifar A.; Zastrozhin M.S.; Zastrozhina A.; Zhang Y.; Zhang Z-J.; Zhong C.; Zuniga Y.M.H.; Murray C.J.L.; Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021,20(10),795-820 - DOI - PubMed
    1. Powers W.J.; Rabinstein A.A.; Ackerson T.; Adeoye O.M.; Bambakidis N.C.; Becker K.; Biller J.; Brown M.; Demaerschalk B.M.; Hoh B.; Jauch E.C.; Kidwell C.S.; Leslie-Mazwi T.M.; Ovbiagele B.; Scott P.A.; Sheth K.N.; Southerland A.M.; Summers D.V.; Tirschwell D.L.; Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2019,50(12),e344-e418 - DOI - PubMed
    1. Hankey G.J.; Stroke. Lancet 2017,389(10069),641-654 - DOI - PubMed
    1. Seners P.; Turc G.; Oppenheim C.; Baron J.C.; Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: A systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry 2015,86(1),87-94 - DOI - PubMed
    1. Lyden P.; Using the national institutes of health stroke scale. Stroke 2017,48(2),513-519 - DOI - PubMed

LinkOut - more resources